Tonix director granted options on 22,700 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tonix Pharmaceuticals Holding Corp. reported that director Carolyn E. Taylor received a grant of stock options covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share and expire on May 12, 2036.
The award was granted under Tonix’s 2026 Stock Incentive Plan and vests on the earlier of the one-year anniversary of the May 12, 2026 grant date and the company’s 2027 Annual Meeting of Stockholders. Following this grant, Taylor holds stock options for 22,700 shares as reported in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 22,700 | $0.00 | $0.00 |
Footnotes (1)
- F1. The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.
Key Figures
Key Terms
Stock Option financial
2026 Stock Incentive Plan financial
exercise price financial
vesting financial
expiration date financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tonix (TNXP) director Carolyn E. Taylor receive in this Form 4 filing?
What is the exercise price of Carolyn E. Taylor’s Tonix (TNXP) stock options?
When do Carolyn E. Taylor’s Tonix (TNXP) stock options vest?
When do the Tonix (TNXP) stock options granted to Carolyn E. Taylor expire?
How many Tonix (TNXP) stock options does Carolyn E. Taylor hold after this grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.